These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 34257540)

  • 1. Landscape of Biomarkers in Non-small Cell Lung Cancer Using Comprehensive Genomic Profiling and PD-L1 Immunohistochemistry.
    Huang RSP; Severson E; Haberberger J; Duncan DL; Hemmerich A; Edgerly C; Ferguson NL; Frampton G; Owens C; Williams E; Elvin J; Vergilio JA; Killian JK; Lin D; Morley S; McEwan D; Holmes O; Danziger N; Cohen MB; Sathyan P; McGregor K; Reddy P; Venstrom J; Anhorn R; Alexander B; Brown C; Ross JS; Ramkissoon SH
    Pathol Oncol Res; 2021; 27():592997. PubMed ID: 34257540
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biomarkers in Breast Cancer: An Integrated Analysis of Comprehensive Genomic Profiling and PD-L1 Immunohistochemistry Biomarkers in 312 Patients with Breast Cancer.
    Huang RSP; Li X; Haberberger J; Sokol E; Severson E; Duncan DL; Hemmerich A; Edgerly C; Williams E; Elvin J; Vergilio JA; Killian JK; Lin D; Hiemenz M; Xiao J; McEwan D; Holmes O; Danziger N; Erlich R; Frampton G; Cohen MB; McGregor K; Reddy P; Cardeiro D; Anhorn R; Venstrom J; Alexander B; Brown C; Pusztai L; Ross JS; Ramkissoon SH
    Oncologist; 2020 Nov; 25(11):943-953. PubMed ID: 32869930
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PD-L1 expression and its relationship with oncogenic drivers in non-small cell lung cancer (NSCLC).
    Jiang L; Su X; Zhang T; Yin X; Zhang M; Fu H; Han H; Sun Y; Dong L; Qian J; Xu Y; Fu X; Gavine PR; Zhou Y; Tian K; Huang J; Shen D; Jiang H; Yao Y; Han B; Gu Y
    Oncotarget; 2017 Apr; 8(16):26845-26857. PubMed ID: 28460468
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PD-L1 expression in patients with non-small-cell lung cancer is associated with sex and genetic alterations: A retrospective study within the Caucasian population.
    Sarova P; Mosleh B; Zehetmayer S; Oberndorfer F; Widder J; Prosch H; Aigner C; Idzko M; Hoda MA; Gompelmann D
    Thorac Cancer; 2024 Jul; 15(20):1598-1606. PubMed ID: 38860475
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive Genomic Profiling Facilitates Implementation of the National Comprehensive Cancer Network Guidelines for Lung Cancer Biomarker Testing and Identifies Patients Who May Benefit From Enrollment in Mechanism-Driven Clinical Trials.
    Suh JH; Johnson A; Albacker L; Wang K; Chmielecki J; Frampton G; Gay L; Elvin JA; Vergilio JA; Ali S; Miller VA; Stephens PJ; Ross JS
    Oncologist; 2016 Jun; 21(6):684-91. PubMed ID: 27151654
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation between immunotherapy biomarker PD-L1 expression and genetic alteration in patients with non-small cell lung cancer.
    Chen H; Ge M; Zhang F; Xing Y; Yu S; Chen C; Zhang H; Wang X; Gao X; Chen F; Chen P; Zhang D; Zhan Q; Zhu Y
    Genomics; 2023 Jul; 115(4):110648. PubMed ID: 37217086
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association of PD-L1 expression with driver gene mutations and clinicopathological characteristics in non-small cell lung cancer: A real-world study of 10 441 patients.
    Ruiz G; Enrico D; Mahmoud YD; Ruiz A; Cantarella MF; Leguina L; Barberis M; Beña A; Brest E; Starapoli S; Mendoza Bertelli A; Tsou F; Pupareli C; Coppola MP; Scocimarro A; Sena S; Levit P; Perfetti A; Aman E; Girotti MR; Arrieta O; Martín C; Salanova R
    Thorac Cancer; 2024 Apr; 15(11):895-905. PubMed ID: 38456253
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pan-cancer analysis of
    Huang RSP; Decker B; Murugesan K; Hiemenz M; Mata DA; Li G; Creeden J; Ramkissoon SH; Ross JS
    J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34130989
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combining Genomic Biomarkers to Guide Immunotherapy in Non-Small Cell Lung Cancer.
    van de Haar J; Mankor JM; Hummelink K; Monkhorst K; Smit EF; Wessels LFA; Cuppen E; Aerts JGJV; Voest EE
    Clin Cancer Res; 2024 Apr; 30(7):1307-1318. PubMed ID: 38300729
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterization of PD-L1 expression in Chinese non-small cell lung cancer patients with PTEN expression as a means for tissue quality screening.
    Zhang XC; Cao X; Sun C; Xie Z; Guo JJ; Yang JJ; Yang XN; Dai HJ; Li SC; Xu XR; Zuo YX; Chen M; Koeppen H; He J; Kiermaier A; Shames D; Cheng G; Wu YL
    Cancer Immunol Immunother; 2018 Mar; 67(3):471-481. PubMed ID: 29214427
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular Diagnostics and Treatment Patterns in Metastatic Non-small Cell Lung Cancer Patients: Real World Evidence from Greece: LACHESIS Study.
    Charpidou A; Mani M; Kokkotou E; Stournara L; Stathelou L; Antoniadou K; Argyropoulos E; Syrigos KN
    Anticancer Res; 2024 May; 44(5):2063-2072. PubMed ID: 38677737
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pan-cancer landscape of
    Huang RSP; Murugesan K; Montesion M; Pavlick DC; Mata DA; Hiemenz MC; Decker B; Frampton G; Albacker LA; Ross JS
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 33972391
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimizing immunofluorescence with high-dynamic-range imaging to enhance PD-L1 expression evaluation for 3D pathology assessment from NSCLC tumor tissue.
    Huang HN; Kuo CW; Hung YL; Yang CH; Hsieh YH; Lin YC; Chang MD; Lin YY; Ko JC
    Sci Rep; 2024 Jul; 14(1):15176. PubMed ID: 38956114
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantification of PD-L1 and PD-1 expression on tumor and immune cells in non-small cell lung cancer (NSCLC) using non-enzymatic tissue dissociation and flow cytometry.
    Chargin A; Morgan R; Sundram U; Shults K; Tsay EL; Ratti N; Patterson BK
    Cancer Immunol Immunother; 2016 Nov; 65(11):1317-1323. PubMed ID: 27565980
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comprehensive genomic profiling of pulmonary spindle cell carcinoma using tissue and plasma samples: insights from a real-world cohort analysis.
    Sun Y; Qin S; Wang S; Pang J; Ou Q; Liang W; Zhong H
    J Pathol Clin Res; 2024 May; 10(3):e12375. PubMed ID: 38661052
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictive Biomarkers for Immune Checkpoint Inhibitors in Metastatic Breast Cancer.
    Sivapiragasam A; Ashok Kumar P; Sokol ES; Albacker LA; Killian JK; Ramkissoon SH; Huang RSP; Severson EA; Brown CA; Danziger N; McGregor K; Ross JS
    Cancer Med; 2021 Jan; 10(1):53-61. PubMed ID: 33314633
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The Impact of Prior Single-Gene Testing on Comprehensive Genomic Profiling Results for Patients with Non-Small Cell Lung Cancer.
    Nesline MK; Subbiah V; Previs RA; Strickland KC; Ko H; DePietro P; Biorn MD; Cooper M; Wu N; Conroy J; Pabla S; Zhang S; Wallen ZD; Sathyan P; Saini K; Eisenberg M; Caveney B; Severson EA; Ramkissoon S
    Oncol Ther; 2024 Jun; 12(2):329-343. PubMed ID: 38502426
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-World Impact of Comprehensive Genomic Profiling on Biomarker Detection, Receipt of Therapy, and Clinical Outcomes in Advanced Non-Small Cell Lung Cancer.
    Wallenta Law J; Bapat B; Sweetnam C; Mohammed H; McBratney A; Izano MA; Scannell Bryan M; Spencer S; Schroeder B; Hostin D; Simon GR; Berry AB
    JCO Precis Oncol; 2024 May; 8():e2400075. PubMed ID: 38754057
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinicopathologic, Genomic, and Immunophenotypic Landscape of ATM Mutations in Non-Small Cell Lung Cancer.
    Ricciuti B; Elkrief A; Alessi J; Wang X; Li Y; Gupta H; Muldoon DM; Bertram AA; Pecci F; Lamberti G; Di Federico A; Barrichello A; Vaz VR; Gandhi M; Lee E; Shapiro GI; Park H; Nishino M; Lindsay J; Felt KD; Sharma B; Cherniack AD; Rodig S; Gomez DR; Shaverdian N; Rakaee M; Bandlamudi C; Ladanyi M; Janne PA; Schoenfeld AJ; Sholl LM; Awad MM; Cheng ML
    Clin Cancer Res; 2023 Jul; 29(13):2540-2550. PubMed ID: 37097610
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current status and progress of PD-L1 detection: guiding immunotherapy for non-small cell lung cancer.
    Qi C; Li Y; Zeng H; Wei Q; Tan S; Zhang Y; Li W; Tian P
    Clin Exp Med; 2024 Jul; 24(1):162. PubMed ID: 39026109
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.